Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 171-176

  Zimbroff, Dan L ^a   Marcus, Ronald N ^b   Manos, George ^b   Stock, Elyse ^b   McQuade, Robert D ^c   Auby, Philippe ^c   Oren, Dan A ^b  

^a Pacific Clinical Research Medical Group   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LORAZEPAM; PLACEBO;

ADULT; AGITATION; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE BURNING; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING;

ACUTE DISEASE; ADULT; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; LORAZEPAM; MALE; NAUSEA; PATIENT DROPOUTS; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; VOMITING;

EID: 34247119312     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b13e318033bd5e     Document Type: Article

References (21)

1. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003;64:3-9.
2. Allen MH, Currier GW, Hughes DH, et al. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract. 2003;9:16-38.
3. Currier GW, Allen MH, Bunney EB, et al. Intramuscular antipsychotics: clinical experience review. J Emerg Med. 2004;27:3-4. quiz S8.
4. Stimmel GL. Benzodiazepines in schizophrenia. Pharmacotherapy. 1996;16:148S-151S. discussion 66S-68S.
5. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003;20:339-346.
6. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61:11-20.
7. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001;155:128-134.
8. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12-18.
9. Brook S, Lucey JV, Gunn KP, Ziprasidone I.M. Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933-941.
10. Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004;19:9-15.
11. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389-397.
12. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with IM haloperidol. Psychopharmacology (Berl). 2006;188:281-292.
13. Tran-Johnson T, Sack D, Marcus R, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind placebo-controlled trial. J Clin Psychiatry. 2007;68:111-119.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
15. Guy W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. National Institute of Mental Health: Rockville, MD; 1976:218-222.
16. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494-504.
17. Corrigan JD, Bogner JA. Factor structure of the Agitated Behavior Scale. J Clin Exp Neuropsychol. 1994;16:386-392.
18. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
19. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65:1207-1222.
20. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997;15:335-340.
21. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997;12:175-179.